COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01535183
Recruitment Status : Unknown
Verified July 2014 by Seoul National University Hospital.
Recruitment status was:  Recruiting
First Posted : February 17, 2012
Last Update Posted : July 14, 2014
Information provided by (Responsible Party):
Seoul National University Hospital

Brief Summary:

The outcome of pediatric refractory or relapsed brain tumor is very dismal. Standard chemotherapy showed poor response to these patients. Although tandem high dose chemotherapy with hematopoietic progenitor stem cell rescues has been chosen as a potentially curative therapy for long term survival and better outcome is expected if tumor burden before transplantation reduced by chemotherapy, effective salvage chemotherapy for tumor reduction is not established yet. Irinotecan is a recently developed topoisomerase I inhibitor, and there are preclinical and phase I, II data which proved practical effects in brain tumors. In those studies, irinotecan was administered alone or in combination with one other drug.

Vincristine, etoposide, carboplatin, and cyclophosphamide have been used in many protocols for brain tumors but the result was very poor in refractory or relapsed cases. However, irinotecan can be effective with these multiple chemotherapeutic agents. According to the pilot study of irinotecan in combination with vincristine, etoposide, carboplatin and cyclophosphamide in the investigators center, 75% percent of total 12 patients reached more than stable disease, and 2 patients got long term complete remission only with this multi-agent combination chemotherapy. But the combination of irinotecan, vincristine, etoposide, carboplatin, and cyclophosphamide is not clinically studied yet especially for pediatric patients. To improve response rate and progression-free survival, the combination chemotherapy of irinotecan, vincristine, etoposide, carboplatin, and cyclophosphamide is designed for pediatric refractory or relapsed brain tumor.

Condition or disease Intervention/treatment Phase
Brain Tumor Drug: Irinotecan combination chemotherapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Irinotecan, Vincristine, Etoposide, Carboplatin, and Cyclophosphamide for Refractory or Relapsed Brain Tumor in Children and Adolescents
Study Start Date : January 2012
Estimated Primary Completion Date : September 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Brain Tumors

Arm Intervention/treatment
Experimental: Irinotecan Drug: Irinotecan combination chemotherapy

Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)

VCR 2㎎/㎡ d0 IV push

Etoposide 100㎎/㎡ d0-d2 IV over 1hr

Carboplatin 450㎎/㎡ d0 IV over 8hrs

Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna

Other Name: Camptosar (Pfizer) or Campto (Yakult Honsha)

Primary Outcome Measures :
  1. To evaluate response rate (more than stable disease) of combination chemotherapy [ Time Frame: every 3 months ]

    - Response Criteria : WHO-based "Macdonald criteria", based on MRI

    1. Complete Response : disappearance of all enhancing tumor
    2. Partial Remission : more than 50 percentage decrease in the tumor measurement compared with the baseline scan
    3. Stable Disease : includes changes that do not meet criteria for CR, PR, or progressive disease (PD)
    4. Progressive Disease : more than 25 percentage increase in tumor measurement compared with the lesion size that defines the nadir, or smallest measurement, in the serial studies

Secondary Outcome Measures :
  1. To evaluate adverse event [ Time Frame: during chemotherapy and every follow up (3 times a week, up to 4 weeks) ]
    - Toxicity evaluation : CTC version 4.0. A copy of the current version of the CTCAE can be downloaded from the CTEP home page (

  2. To evaluate progression-free survival [ Time Frame: until last follow up (at least 1year) ]
    - Kaplan-Meier method will be used for analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of brain tumor : embryonal brain tumor (medulloblastoma, CNS PNET, ATRT, etc), intracranial germ cell tumor
  • Relapse or refractory state
  • Prior therapy : Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. Patients are eligible 8 weeks from the day of stem cell infusion for autologous stem cell transplant, if hematological and all other eligibility criteria are met.
  • Performance status: ECOG 0-2.
  • Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases.

    1. Heart: a shortening fraction ≥ 28%
    2. Liver: total bilirubin < 2 × upper limit of normal; ALT < 3 × upper limit of normal.
    3. Kidney: creatinine <2 × normal
  • Patients must lack any active viral infections or active fungal infection.
  • Patients (or one of parents if patients age < 20) should sign informed consent.

Exclusion Criteria:

  • Pregnant or nursing women.
  • Malignant (except brain tumor) or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.
  • Psychiatric disorder that would preclude compliance.
  • Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01535183

Layout table for location information
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Chongno-gu, Korea, Republic of, 110-744
Contact: Hyoung Jin Kang, M.D., Ph.D    82-2-2072-3304   
Contact: Hyery Kim, M.D.    82-2-2072-3452   
Sponsors and Collaborators
Seoul National University Hospital
Layout table for investigator information
Principal Investigator: Hyoung Jin Kang, M.D., ph.D Seoul National University Hospital

Layout table for additonal information
Responsible Party: Seoul National University Hospital Identifier: NCT01535183    
Other Study ID Numbers: SNUCH-1201
First Posted: February 17, 2012    Key Record Dates
Last Update Posted: July 14, 2014
Last Verified: July 2014
Keywords provided by Seoul National University Hospital:
brain tumor
salvage therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors